Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne C Armstrong

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Psycho-Oncology|September 7, 2010
Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancerRebecca J Lee, Ann Wakefield, Sharon Foy, et al.
International Journal of Cancer|August 10, 2004
Use of adenoviruses encoding CD40L or IL-2 against B cell lymphomaEl Kahina Meziane, Tapan Bhattacharyya, Anne C Armstrong, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2002
Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitopeAnne C Armstrong, Said Dermime, Christopher G Allinson, et al.
Breast Cancer Research and Treatment|January 29, 2010
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancerRuth E Board, Andrew M Wardley, J Michael Dixon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>-</sup> Advanced Breast CancerErika P Hamilton, Manish R Patel, Anne C Armstrong, et al.
Oncotarget|April 30, 2016
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimenAnthony Kong, Daniel Rea, Samreen Ahmed, et al.
Journal of Mammary Gland Biology and Neoplasia|September 30, 2016
Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to MetastasisRachel Eyre, Denis G Alférez, Kath Spence, et al.
Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.
JCO Precision Oncology|May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast CancerJacqueline A Shaw, Karen Page, Evie Wren, et al.
Molecular Oncology|December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detectionAndi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Psycho-Oncology|September 7, 2010
Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancerRebecca J Lee, Ann Wakefield, Sharon Foy, et al.
International Journal of Cancer|August 10, 2004
Use of adenoviruses encoding CD40L or IL-2 against B cell lymphomaEl Kahina Meziane, Tapan Bhattacharyya, Anne C Armstrong, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2002
Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitopeAnne C Armstrong, Said Dermime, Christopher G Allinson, et al.
Breast Cancer Research and Treatment|January 29, 2010
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancerRuth E Board, Andrew M Wardley, J Michael Dixon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>-</sup> Advanced Breast CancerErika P Hamilton, Manish R Patel, Anne C Armstrong, et al.
Oncotarget|April 30, 2016
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimenAnthony Kong, Daniel Rea, Samreen Ahmed, et al.
Journal of Mammary Gland Biology and Neoplasia|September 30, 2016
Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to MetastasisRachel Eyre, Denis G Alférez, Kath Spence, et al.
Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.
JCO Precision Oncology|May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast CancerJacqueline A Shaw, Karen Page, Evie Wren, et al.
Molecular Oncology|December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detectionAndi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
Pageof 3